Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Efficacy and safety of edifoligide.

Desai ND, Fremes SE.

JAMA. 2006 Apr 5;295(13):1514; author reply 1514-5. No abstract available.

PMID:
16595752
2.

Efficacy and safety of edifoligide.

Lau GT, Kritharides L.

JAMA. 2006 Apr 5;295(13):1513-4; author reply 1514-5. No abstract available.

PMID:
16595750
3.

Efficacy and safety of edifoligide.

Parolari A, Alamanni F, Tremoli E, Biglioli P.

JAMA. 2006 Apr 5;295(13):1513; author reply 1514-5. No abstract available.

PMID:
16595751
4.

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators.

JAMA. 2005 Nov 16;294(19):2446-54.

PMID:
16287955
5.

Gene therapy and vein graft patency in coronary artery bypass graft surgery.

Conti VR, Hunter GC.

JAMA. 2005 Nov 16;294(19):2495-7. No abstract available.

PMID:
16287962
6.

Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial.

Karski J, Djaiani G, Carroll J, Iwanochko M, Seneviratne P, Liu P, Kucharczyk W, Fedorko L, David T, Cheng D.

J Thorac Cardiovasc Surg. 2005 Aug;130(2):309-14.

7.
8.

Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.

Conte MS, Lorenz TJ, Bandyk DF, Clowes AW, Moneta GL, Seely BL.

Vasc Endovascular Surg. 2005 Jan-Feb;39(1):15-23.

9.

Augmentation of coronary bypass graft flow induced by dipyridamole and its relation to bypass graft patency.

Suma H, Takeuchi A, Sasaki S, Asada K, Suwa M, Hirota Y.

Jpn J Surg. 1988 Mar;18(2):172-8.

PMID:
3260634
10.

Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass.

Hoel AW, Conte MS.

Cardiovasc Drug Rev. 2007 Fall;25(3):221-34. Review.

PMID:
17919257
11.

Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study.

Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, et al.

Circulation. 1988 Jun;77(6):1324-32.

PMID:
3286040
12.

Arterial and venous conduits for coronary artery bypass. A current review.

Cooper GJ, Underwood MJ, Deverall PB.

Eur J Cardiothorac Surg. 1996;10(2):129-40. Review.

PMID:
8664004
13.

A stand-up collar around the saphenous vein graft.

Terada Y, Sekii H, Ichikawa S, Higashiue S.

Gen Thorac Cardiovasc Surg. 2010 Oct;58(10):546-7. doi: 10.1007/s11748-009-0579-x. Epub 2010 Oct 13.

PMID:
20941572
14.

[Vascular biology of coronary bypass grafts. Literature review].

Barandon L, Kindo M, Perrault LP, Hebert Y, Cartier R, Bouchard D, Demers P, Pagé P, Carrier M, Pellerin M.

Arch Mal Coeur Vaiss. 2004 Dec;97(12):1206-15. Review. French.

PMID:
15669362
15.

Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ.

Lancet. 1999 Oct 30;354(9189):1493-8.

PMID:
10551494
16.

Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.

Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, et al.

Circulation. 1989 Nov;80(5):1190-7.

PMID:
2680158
17.

Internal mammary artery and saphenous vein graft patency. Effects of aspirin.

Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S, et al.

Circulation. 1990 Nov;82(5 Suppl):IV237-42.

PMID:
2225410
18.

Effect of combined use of statins and angiotensin converting enzyme inhibitors on saphenous vein graft patency and its mechanism.

Özeren M, Sucu N.

Ann Thorac Surg. 2012 Jul;94(1):330; author reply 330-1. doi: 10.1016/j.athoracsur.2011.12.018. No abstract available.

PMID:
22735007
19.

The future of saphenous vein graft for coronary artery.

Souza DS, Gomes WJ.

Rev Bras Cir Cardiovasc. 2008 Jul-Sep;23(3):III-VII. English, Portuguese. No abstract available.

PMID:
19082314
20.

The biology of saphenous vein graft occlusion: etiology and strategies for prevention.

Bryan AJ, Angelini GD.

Curr Opin Cardiol. 1994 Nov;9(6):641-9. Review.

PMID:
7819622

Supplemental Content

Support Center